OM
CRSP icon

Opaleye Management’s CRISPR Therapeutics CRSP Stock Holding History

Opaleye Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-281,000
Closed -$6.6M – 40
2017
Q4 		$6.6M Buy
+281,000
New +$5.34M 2.11% 15

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Opaleye Management's CRSP Position: Q1 2018 in Review

Opaleye Management sold out of CRISPR Therapeutics (CRSP) in Q1 2018, closing a stake of 281,000 shares — an estimated $6.6M sold.

Opaleye Management first reported a position in CRSP in Q4 2017 and held it in 1 quarter. The position peaked at $6.6M in Q4 2017. 135 funds tracked by Wall St. Rank hold CRSP as of Q1 2018.

  • Opaleye Management reported no remaining CRISPR Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Opaleye Management sold 281,000 CRISPR Therapeutics shares in Q1 2018, an estimated $6.6M.
  • Opaleye Management first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 1 quarter.
  • Opaleye Management's CRISPR Therapeutics position peaked at $6.6M in Q4 2017.
  • 135 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2018.

Based on Opaleye Management's 13F filing for Q1 2018, filed 14 May 2018.